Median Number of Months of Progression-free Survival (PFS) From randomization to evidence of disease progression/death or date of last tumor assessment (up to 26 months). [clinicaltrials_resource:517577f3f0577ead12433ba2d925d706]
Interval between randomization date & earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): >=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments & were still alive, date of randomization used.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Median Number of Months of Progression-free Survival (PFS) From randomization to evidence of disease progression/death or date of last tumor assessment (up to 26 months). [clinicaltrials_resource:517577f3f0577ead12433ba2d925d706]
Interval between randomization date & earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): >=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments & were still alive, date of randomization used.
Bio2RDF identifier
517577f3f0577ead12433ba2d925d706
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:517577f3f0577ead12433ba2d925d706
measure [clinicaltrials_vocabulary:measure]
Median Number of Months of Progression-free Survival (PFS)
time frame [clinicaltrials_vocabulary:time-frame]
From randomization to evidence ...... assessment (up to 26 months).
description
Interval between randomization ...... e, date of randomization used.
identifier
clinicaltrials_resource:517577f3f0577ead12433ba2d925d706
title
Median Number of Months of Pro ...... assessment (up to 26 months).
@en
type
label
Median Number of Months of Pro ...... 577f3f0577ead12433ba2d925d706]
@en